Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary

$837,696U19FY2010AINIH

Wits Health Consortium (Pty), Ltd, Johannesburg

Investigators

Linked publications & trials

Paper 38905492 Paper 36928069 Paper 36829110 Paper 34259393 Paper 34204740 Paper 34107770 Paper 32430069 Paper 31776265 Paper 31441231 Paper 30417710 Paper 29375341 Paper 29209922 Paper 29033797 Paper 28979264 Paper 28719495 Paper 27538904 Paper 26959509 Paper 26671450 Paper 25923117 Paper 25910923 Paper 25697412 Paper 25538273 Paper 25389804 Paper 25053739 Paper 24935904 Paper 24925044 Paper 24924772 Paper 24867158 Paper 24758715 Paper 24609068 Paper 24602844 Paper 24595047 Paper 24468996 Paper 24334155 Paper 24295968 Paper 24209829 Paper 24047763 Paper 23572010 Paper 23249919 Paper 23228814 Paper 22990075 Paper 22984637 Paper 22879816 Paper 22618567 Paper 22614886 Paper 22479548 Paper 22293461 Paper 22173039 Paper 22114687 Paper 22103994 Paper 22103326 Paper 22071585 Paper 22016763 Paper 21996698 Paper 21969875 Paper 21957868 Paper 21943845 Paper 21818180 Paper 21787822 Paper 21786731 Paper 21756508 Paper 21685540 Paper 21678737 Paper 21631918 Paper 21552185 Paper 21436714 Paper 21414276 Paper 21346513 Paper 21317585 Paper 21293199 Paper 21288857 Paper 21150593 Paper 21109173 Paper 21084996 Paper 21080998 Paper 21078148 Paper 21072191 Paper 20936108 Paper 20926954 Paper 20827216 Paper 20706597 Paper 20613459 Paper 20604716 Paper 20583920 Paper 20582246 Paper 20558626 Paper 20557927 Paper 20480433 Paper 20386425 Paper 20332365 Paper 20202297 Paper 20128273 Paper 20113978 Paper 20046147 Paper 20046144 Paper 20017918 Paper 20003695 Paper 20001527 Paper 19952711 Paper 19935274

Abstract

The overall aim is to evaluate whether early therapy given for a limited time will improve HIV prognosis in the longer term by deferring the time that children need to start life-long ART. The primary objective compares time to failure of first line ART (due to clinical or immunological disease progression, or regimen-limiting ART toxicities) or death among three randomized arms (infants who receive early ART for a limited time in Arms 2 and 3 and infants in whom ART is deferred until clinical or immunological disease progression in Arm 1);the primary endpoint is time taken to reach the objective.

View original record on NIH RePORTER →